menu
    • menu
    [{"orgOrder":0,"company":"Replay Bio","sponsor":"KKR","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Financing","leadProduct":"AAV-based Gene Therapy","moa":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Replay Bio","amount2":0.059999999999999998,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Replay Bio \/ KKR","highestDevelopmentStatusID":"1","companyTruncated":"Replay Bio \/ KKR"},{"orgOrder":0,"company":"Replay Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"SynHSV Gene Therapy","moa":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Replay Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Replay Bio \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Replay Bio \/ Not Applicable"},{"orgOrder":0,"company":"Replay Bio","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Funding","leadProduct":"iPSC-derived Immune Cell Therapy","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Replay Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Replay Bio \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Replay Bio \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Replay Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"TCR-NK Cell Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Replay Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Replay Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Replay Bio \/ Not Applicable"},{"orgOrder":0,"company":"Replay Bio","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"NY-ESO-1 TCR\/IL-15 NK Cell Therapy","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Replay Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Replay Bio \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"5","companyTruncated":"Replay Bio \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Replay Bio","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"NY-ESO-1 TCR\/IL-15 NK Cell Therapy","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Replay Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Replay Bio \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"5","companyTruncated":"Replay Bio \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Replay Bio","sponsor":"Jura Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"T-cell Receptor Based Therapy","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Replay Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Replay Bio \/ Replay Bio","highestDevelopmentStatusID":"3","companyTruncated":"Replay Bio \/ Replay Bio"},{"orgOrder":0,"company":"Replay Bio","sponsor":"Syena","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Replay Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Replay Bio \/ Syena","highestDevelopmentStatusID":"7","companyTruncated":"Replay Bio \/ Syena"},{"orgOrder":0,"company":"Replay Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Decitabine","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Replay Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Replay Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Replay Bio \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Replay Bio

    Menu

    Replay Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Replay Bio

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Replay Bio

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SY-307,Fludarabine Phosphate,Decitabine

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Replay and MD Anderson Get FDA Clearance for PRAME-Targeted TCR-NK Therapy

                            Details : SY-307, a PRAME TCR/IL-15 NK cell therapy, is investigated in relapsed/refractory AML and MDS patients after lymphodepletion with fludarabine/cyclophosphamide and decitabine.

                            Brand Name : SY-307

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            April 30, 2024

                            Lead Product(s) : SY-307,Fludarabine Phosphate,Decitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Replay Bio

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Replay Bio

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NY-ESO-1 TCR/IL-15,Fludarabine Phosphate,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Syena

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Replay's Cell Therapy Company Syena Doses First Patient in Phase 1/2 Study

                            Details : NY-ESO-1 TCR/IL-15 NK, an engineered T-cell receptor natural killer (TCR-NK) cell therapy, which is being evaluated for the treatment of patients with relapsed or refractory multiple myeloma.

                            Brand Name : NY-ESO-1 TCR/IL-15

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            March 11, 2024

                            Lead Product(s) : NY-ESO-1 TCR/IL-15,Fludarabine Phosphate,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Syena

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Replay Bio

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Replay Bio

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : T-cell Receptor Based Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Recipient : Jura Bio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Replay Announces Partnership Between Product Company Syena and JURA Bio to Advance T Cell Receptor NK Therapie...

                            Details : The collaboration aims to develop T cell receptor (TCR) based NK therapies in cancer by leveraging JURA Bio’s T cell receptor discovery platform to discover and develop innovative therapies by applying AI/machine learning.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            September 21, 2023

                            Lead Product(s) : T-cell Receptor Based Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Recipient : Jura Bio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Replay Bio

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Replay Bio

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NY-ESO-1 TCR/IL-15 NK Cell Therapy

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : The University of Texas MD Anderson Cancer Center

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Replay and MD Anderson Announce FDA Clearance of IND Application for First-in-Class T-Cell Receptor Natural Ki...

                            Details : NY-ESO-1 TCR/IL-15 NKs are adoptive Natural Killer (NK) cells expressing an affinity-enhanced T-cell receptor (TCR) reactive directed against the NY-ESO-1-specific cord blood-derived NK cells.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            July 24, 2023

                            Lead Product(s) : NY-ESO-1 TCR/IL-15 NK Cell Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : The University of Texas MD Anderson Cancer Center

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Replay Bio

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Replay Bio

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NY-ESO-1 TCR/IL-15 NK Cell Therapy

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : The University of Texas MD Anderson Cancer Center

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Replay and MD Anderson Announce FDA Clearance of IND Application for First-in-class T-Cell Receptor Natural Ki...

                            Details : NY-ESO-1 TCR/IL-15 NK is an engineered T-Cell Receptor Natural Killer (TCR-NK) cell therapy for advanced synovial sarcoma and myxoid/round cell liposarcoma.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            June 20, 2023

                            Lead Product(s) : NY-ESO-1 TCR/IL-15 NK Cell Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : The University of Texas MD Anderson Cancer Center

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Replay Bio

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Replay Bio

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TCR-NK Cell Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            KKR-backed Replay and MD Anderson Form New Product Company Syena to Pioneer First-In-Class TCR-NK Cell Therapy

                            Details : TCR-NK cell platform targets a selection of validated cancer neoantigens, including NY-ESO-1, and additional undisclosed TCRs. The NY-ESO-1 program in hematological malignancies and solid tumors.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            February 14, 2023

                            Lead Product(s) : TCR-NK Cell Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Replay Bio

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Replay Bio

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : iPSC-derived Immune Cell Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Bill & Melinda Gates Foundation

                            Deal Size : $1.5 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Replay Receives $1.5 Million Grant For Its Hypoimmunogenic Technology Platform

                            Details : Replay’s uCell™ platform is an off-the-shelf, genomically rewritten, hypoimmunogenic technology that allows allogeneic donor-derived primary cells and iPSCs (Induced Pluripotent Stem Cells) to be made immune silent.

                            Brand Name : uCell

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            November 28, 2022

                            Lead Product(s) : iPSC-derived Immune Cell Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Bill & Melinda Gates Foundation

                            Deal Size : $1.5 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Replay Bio

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Replay Bio

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SynHSV Gene Therapy

                            Therapeutic Area : Genetic Disease

                            Study Phase : Discovery

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Replay Launches Big DNA HSV Gene Therapy Company, Telaria, Focused on Rare Skin Diseases

                            Details : Telaria is the second of Replay’s four synHSV™ gene therapy product companies and its launch follows that of Eudora, a company targeting genetic diseases of the retina.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            November 21, 2022

                            Lead Product(s) : SynHSV Gene Therapy

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Discovery

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Replay Bio

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Replay Bio

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AAV-based Gene Therapy

                            Therapeutic Area : Genetic Disease

                            Study Phase : Undisclosed

                            Sponsor : KKR

                            Deal Size : $55.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Replay Launches with $55 Million Seed to Reprogram Biology by Writing and Delivering Big DNA

                            Details : Replay’s synHSV™ technology, a high payload capacity HSV vector capable of delivering up to 30 times the payload of AAV, is utilized by Replay’s four gene therapy product companies, bringing big DNA treatments to diseases affecting the skin, eye, b...

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            July 25, 2022

                            Lead Product(s) : AAV-based Gene Therapy

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Undisclosed

                            Sponsor : KKR

                            Deal Size : $55.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth